BioMarin Pharmaceutical Partners with Veeva Systems to Enhance Drug Development Efficiency

BioMarin Pharmaceuticals and Veeva Systems Forge a Strategic Partnership to Accelerate Drug Development

BioMarin Pharmaceutical Inc. and Veeva Systems have announced a long-term partnership aimed at enhancing the efficiency of drug development and commercialization for rare genetic disorders. This collaboration builds on their existing relationship and focuses on leveraging Veeva's technological capabilities to streamline BioMarin's operations. By utilizing advanced software, data analytics, and consulting services provided by Veeva, BioMarin seeks to optimize the experiences of healthcare professionals and patients, thus speeding up the delivery of transformative therapies to the market.

Alexander Hardy, CEO of BioMarin, emphasizes that this partnership signifies a pivotal moment in their ongoing digital transformation. By integrating Veeva's technological expertise with BioMarin's scientific knowledge, the companies aim to improve their agility and operational efficiency. This strategic alignment allows BioMarin to better respond to the urgent needs of patients suffering from rare diseases, ultimately enhancing the speed and effectiveness of their innovative drug development processes. Hardy highlights that the collaboration is not only about operational improvements but also about creating lasting value for patients and healthcare providers alike.

Peter Gassner, CEO of Veeva Systems, expresses enthusiasm for the partnership, noting that it is rooted in shared values such as product excellence and customer success. Veeva, which specializes in providing cloud-based solutions for the life sciences sector, has a proven track record of serving over 1,500 clients, ranging from large biopharmaceutical companies to emerging biotech innovators. As both companies aim to make significant advancements in therapeutic innovation, this partnership represents a strategic leap forward, promising enhanced capabilities in developing and delivering essential therapies to patients worldwide.

In addition to their collaboration, BioMarin continues to focus on its robust clinical pipeline and commitment to addressing genetically based disorders. With eight commercial therapies already available, the company is well-positioned to make a substantial impact in the biotechnology field. Veeva, recognized as a Public Benefit Corporation, remains dedicated to balancing stakeholder interests while driving growth and innovation in life sciences. Together, these two organizations are poised to redefine standards in drug development, ensuring that critical therapies reach those in need more swiftly than ever before.